Drug detox for Miami — substance-specific protocols, not one-size-fits-all.

For Miami clients — whether coming from Brickell, Coral Gables, Aventura, or Pinecrest — RECO Island offers a 50-mile geographic reset from the local using environment paired with substance-specific medical detox under physician supervision. Detox flows directly into residential treatment on the same Delray Beach campus with no waitlist and no third-party transfer. MAT is initiated during detox where indicated — buprenorphine for OUD, extended-release naltrexone for AUD — and continued through the full continuum. Small-census, physician-led, and coordinated end-to-end.

The drive from Brickell, Coral Gables, or Coconut Grove up I-95 to RECO Island’s Delray Beach campus runs about 50 miles and 65 minutes. For most Miami clients, that distance is the point — putting geographic space between the person and the social scene, the dealers, and the using cues is part of the clinical rationale for residential care rather than a daily commute. RECO Island’s drug detox program is built for that pattern: physician-supervised withdrawal management immediately followed by in-house residential treatment on the same campus, with no waitlist between phases and no transfer to an outside facility.

Substance-specific withdrawal protocols

Opioid, benzodiazepine, and stimulant withdrawal are clinically distinct syndromes with distinct management. Opioid withdrawal — while intensely uncomfortable — is rarely medically dangerous in an otherwise healthy adult. RECO Island’s opioid detox uses COWS-guided (Clinical Opiate Withdrawal Scale) buprenorphine induction, timed to the point where objective withdrawal scores 8–12, then titrated over 24–72 hours to a maintenance dose that suppresses craving without precipitating withdrawal. Fentanyl-adulterated presentations often require a slower induction, or a low-dose “microdosing” strategy, to avoid precipitated withdrawal driven by fentanyl’s atypical redistribution from adipose tissue.

Benzodiazepine withdrawal is the opposite problem: subjectively milder in the early days but carrying real risk of seizures, autonomic instability, and, in severe cases, a delirium indistinguishable from alcohol withdrawal DTs. The protocol at RECO Island is not abrupt discontinuation. Short-acting benzodiazepines (alprazolam, lorazepam) are converted to a long half-life agent — typically clonazepam or diazepam — and tapered over one to several weeks depending on daily dose, duration of use, and prior withdrawal history.

Stimulant withdrawal from cocaine or methamphetamine has no FDA-approved medication protocol. What patients need is not a drug — it is clinical structure through the crash: hypersomnia lasting days, anhedonia, profound depression, and craving spikes that peak around days 3–5. Supportive medical management, sleep protection, nutritional restoration, and early behavioral engagement using CBT and Motivational Interviewing do the actual work. Where depression persists beyond the acute window, sertraline or bupropion may be initiated after psychiatric evaluation.

Polysubstance detox and the sequencing decision

Single-substance presentations are increasingly rare. A typical admission from South Florida involves some combination of alcohol, a benzodiazepine (frequently non-prescribed), an opioid (now more often fentanyl than heroin), and often cocaine or methamphetamine layered on top. Running a generic detox protocol across all of them is unsafe and clinically indefensible.

The sequencing principle is straightforward: manage the life-threatening withdrawals first. Alcohol withdrawal is stratified by CIWA-Ar score and managed with a symptom-triggered benzodiazepine taper. Benzodiazepine withdrawal proceeds on the long-half-life conversion taper described above. Opioid MAT is initiated concurrently — buprenorphine timing has to be threaded carefully around the alcohol and benzodiazepine taper to avoid oversedation. Stimulant withdrawal is managed supportively in parallel.

Every polysubstance detox at RECO Island is planned by the admitting physician before the first dose is administered, using ASAM Criteria dimensional assessment — Dimensions 1 through 3 in particular: acute intoxication and withdrawal potential, biomedical conditions, and emotional/behavioral/cognitive acuity — and documented in the medical record. Nursing runs symptom-triggered scales every shift and escalates to the on-call physician on defined thresholds.

Medical comorbidity is the norm, not the exception

The admission history for most detox patients includes several years of no primary care contact. Chronic substance use produces predictable medical sequelae: hepatitis C from injection drug use, cardiovascular disease and cardiomyopathy from stimulant use, hypertension, poorly controlled diabetes, chronic pain that was under-treated or self-managed with opioids, malnutrition, dental disease, and sleep-disordered breathing. Detox is often the first medical evaluation the patient has had in years.

RECO Island’s admission workup includes full labs (CBC, CMP, hepatic panel, HIV, hepatitis A/B/C serologies, urinalysis, urine drug screen), EKG when clinically indicated, and a full physical examination by the admitting physician. Findings are managed concurrently rather than deferred — hepatitis C referred into treatment (now curable with 8–12 weeks of direct-acting antiviral therapy), hypertension initiated on medication, diabetes stabilized, chronic pain re-evaluated for non-opioid management strategies.

Co-occurring psychiatric illness is assessed with the same rigor. PHQ-9 and GAD-7 are administered on admission; ASRS screens for adult ADHD where indicated. Bipolar disorder, PTSD, and psychotic-spectrum illness are common comorbidities that are stabilized with appropriate pharmacotherapy — lithium or quetiapine for mood stabilization, sertraline for co-occurring depression or PTSD, aripiprazole or olanzapine where indicated — alongside the addiction treatment itself.

The handoff into residential and MAT continuation

Detox produces safe withdrawal. It does not produce recovery. The published relapse rate for medical detox as a standalone intervention — no residential, no MAT, no structured follow-up — is high enough that the clinical community has largely stopped offering detox-only admissions.

RECO Island’s model is integrated: detox flows directly into residential treatment on the same campus, with no waitlist, no discharge home in between, and no transfer to an outside facility. MAT is initiated during detox where clinically indicated — buprenorphine for opioid use disorder, extended-release naltrexone for alcohol use disorder or for OUD after an adequate opioid-free window — and continued through residential and the step-down PHP and IOP phases.

Behavioral treatment during residential draws on CBT for relapse prevention, DBT skills for emotion regulation and distress tolerance where trauma and personality features are prominent, MI throughout, EMDR or trauma-focused CBT where trauma is a primary driver, and ACT for values-based commitment. At discharge, MAT is transitioned to a community prescriber near the client’s Miami residence with a warm handoff — a scheduled first appointment, medical records forwarded, and case management follow-up — rather than a printed referral list.

What to expect on admission from Miami

Most Miami admissions travel up by car — a family member driving, or the family arriving together. Intake typically takes two to three hours: medical evaluation by the admitting physician, nursing assessment with CIWA-Ar and COWS baselines, psychiatric screen, ASAM dimensional documentation, and a detailed review of substance use, prior withdrawal history, medications, and psychiatric history before the first dose of any medication is administered.

Personal belongings are inventoried and contraband is removed. Phones are typically held during the acute detox window and returned as clinically appropriate. Family communication runs through the assigned case manager during the first days rather than direct phone contact — not to isolate the client but to protect the clinical environment during the most physiologically vulnerable window.

Insurance and admissions from Miami

RECO Island verifies benefits before admission for most major commercial plans held by Miami residents — Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. Verification produces a written estimate covering deductible, coinsurance, expected residential day-rate share, and the initial length-of-stay authorization based on ASAM medical necessity, so the client and family know the numbers before the intake conversation ends rather than after admission.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.